To access this element change to forms mode OFF
Grant Award View - GA52671
Designing Chimeric Antigen Receptor T cells for Diffuse Intrinsic...
GA ID:
GA52671
Agency:
Cancer Australia
Approval Date:
29-Apr-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
6-May-2019 to 5-May-2022
Value (AUD):
$592,388.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Designing Chimeric Antigen Receptor T cells for Diffuse Intrinsic Pontine Glioma
Purpose:
Immunotherapy using genetically engineered killer T cells, redirected towards a patient’s tumour, has revolutionised the way we treat cancer. These treatments have been very effective with rapid translation into the clinic but have not been applied to paediatric diffuse pontine glioma (DIPG) where outcomes are the worst for any diagnosis of childhood. This research will help design better therapies for paediatric brain cancer patients.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Melbourne
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA